Association of the circulating lipid panel, PCPro, with clinical outcomes www.annalsofoncology.org/article/S092... post-hoc analysis of ENZAMET found that plasma lipid biomarker PCPro was associated with poorer outcomes in patients with metastatic hormone-sensitive #ProstateCancer

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk jamanetwork.com/journals/jam... The field continues to evolve with the development of novel therapeutic agents, broader clinical indications, and deeper integration of nuclear imaging w/ tx

Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence & Distant Metastases in Biochemical Recurrence of #ProstateCancer After Definitive Treatment www.sciencedirect.com/science/arti... Findings underscore importance of PSA stratification

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive #ProstateCancer : the randomized, double-blind, phase III KEYNOTE-991 study annalsofoncology.org/article/S092...

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy jamanetwork.com/journals/jam... findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT #ProstateCancer @silkegillessen.bsky.social 🚨

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography #ProstateCancer Molecular Imaging Standardized Evaluation (PPP2) www.sciencedirect.com/science/arti... PPP2 offers a robust tool for 3- and 5-year survival prediction

PEACE V–STORM: Salvage metastasis-directed therapy versus elective nodal radiotherapy☢️for oligorecurrent nodal #ProstateCancer metastases out on Lancet Oncology www.thelancet.com/journals/lan... Findings suggest ENRT may be a promising standard approach pending confirmation in a phase 3 trial.

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer @ascocancer.bsky.social Update ascopubs.org/doi/full/10.... Updated ASCO guideline provides evidence-based recommendations for the systemic treatment of patients with metastatic castration-resistant #ProstateCancer

Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer aacrjournals.org/cancerres/ar... Findings highlight promise of this integrative approach for developing non-invasive, clinically feasible diagnostic tools.

Racial disparities in #ProstateCancer in the UK and the USA nature.com/articles/s41... paper emphasizes that addressing these inequities requires systemic change: dismantling structural racism, increasing representation in clinical research and healthcare workforce @silkegillessen.bsky.social

Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for #ProstateCancer jnm.snmjournals.org/content/66/4... These findings support its potential as a next-generation PSMA-targeted therapy with improved tumor-to-kidney uptake ratios and enhanced antitumor activity.

Targeting the tumour cell surface in advanced prostate cancer out on nature reviews urology www.nature.com/articles/s41... A deeper understanding of the dynamic nature of these targets could also inform future combination strategies.

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication www.fda.gov/drugs/resour... FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer who have been treated with ARPI

Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial jamanetwork.com/journals/jam... These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis. #ProstateCancer

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive #ProstateCancer (TITAN) acsjournals.onlinelibrary.wiley.com/doi/full/10.... findings suggest that baseline bone metastasis count may help identify optimal candidates for apalutamide tx in mCSPC.

Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium sciencedirect.com/science/arti... Finds that isodose regimens, like 60 Gy in 20 fractions, are recommended as the standard for localized #ProstateCancer

Stereotactic body radiotherapy for oligoprogressive disease in androgen suppressed prostate cancer: Primary endpoint analysis of the TRAP trial t.co/tzTr4MmoZi TRAP Results showed a median progression-free survival (PFS) of 6.4 months, with 39% of patients maintaining PFS beyond 12 months.

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for #ProstateCancer and Mortality Risk jamanetwork.com/journals/jam... Study suggests extending PSA assessment to at least 3 months post-RP to minimize overtreatment @barbaramelao.bsky.social @yukselurun.bsky.social

Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy jnm.snmjournals.org/content/66/3... The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. #ProstateCancer

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. www.nature.com/articles/s41... Results suggest that SBRT may be a viable option for treating omCRPC after progression compared to systemic therapy

The Germline and Somatic Origins of Prostate Cancer Heterogeneity out on CANCER DISCOVERY aacrjournals.org/cancerdiscov... The findings suggest that both high- and low-grade tumors originate from a common pre-malignant field, shaped by germline genomics and mutation timing. #ProstateCancer

Heterogeneity of the Treatment Effect w/ PARP Inhibitors in Metastatic Castration-resistant #ProstateCancer sciencedirect.com/science/arti... Overall, BRCA alterations confer the most substantial survival benefit, while minimal or no benefits were observed in patients with ATM or CHEK2 alterations

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant #ProstateCancer ascopubs.org/doi/pdf/10.1... The update is based on a trial by Sartor et al., which showed improved PFS and OS in patients with PSMA-positive mCRPC after a median follow-up of 20.9 months.

Oncology Here & Now🎙️ We interview Drs. @silkegillessen.bsky.social 🇨🇭& @aureliusomlin.bsky.social 🇨🇭and delve into Topics & evolution of Advanced #ProstateCancer Consensus Conference @apccc.bsky.social @barbaramelao.bsky.social @yukselurun.bsky.social @achoud72.bsky.social youtu.be/Pxzzecwqqkk?...

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men W/ Suspected #ProstateCancer jamanetwork.com/journals/jam... Study finds men w/ negative MRI who avoided biopsy were not at increased risk of csPCa, supporting safety of an MRI-1st diagnostic approach when combined with systematic FU

Functional outcomes after primary vs delayed robot-assisted radical prostatectomy following active surveillance academic.oup.com/jncics/advan... Suggest active surveillance doesntt have significant detrimental effect on functional outcomes, supportin for men w/low & favorable intermediate-risk PCa

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening jamanetwork.com/journals/jam... Findings suggest that continuing PSA screening in older men may be unnecessary for those with low PSA values before age 70. #ProstateCancer

Trends in #ProstateCancer Incidence and Mortality Rates Out on JAMA Network jamanetwork.com/journals/jam... Findings underscore need for improved prostate cancer screening strategies to address the rising incidence of distant-stage disease Ping @yukselurun.bsky.social @barbaramelao.bsky.social

Genetic testing in prostate cancer management: Considerations informing primary care acsjournals.onlinelibrary.wiley.com/doi/10.3322/... Review discusses the role of genetic testing in personalized PC care, the need for comprehensive family histories, and the integration of genetic counseling

Is there a role of PSMA-PET in focal therapy planning and follow-up? A Review out on Prostate Cancer www.nature.com/articles/s41... Systematic review aims to summarize current applications of PSMA-PET in FT and its future perspectives. @oncoalert.bsky.social 🚨 @barbaramelao.bsky.social

Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial www.sciencedirect.com/science/arti...

Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources🇧🇷 ascopubs.org/doi/full/10.... Findings suggest that oral cyclophosphamide remains a viable option, especially with limited resources @barbaramelao.bsky.social

Physics-Informed Autoencoder for Prostate Tissue Microstructure Profiling with Hybrid Multidimensional MRI pubs.rsna.org/doi/full/10.... #ProstateCancer @barbaramelao.bsky.social @achoud72.bsky.social @yukselurun.bsky.social @drnataliagandur.bsky.social

Homologous recombination repair status in metastatic #ProstateCancer by NGS and functional immunofluorescence Method offers functional approach for identifying HRR deficiency in clinical practice, with potential prognostic and therapeutic implications for mPC patients www.cell.com/cell-reports...

High-purity CTC RNA sequencing identifies #ProstateCancer lineage phenotypes prognostic for clinical outcomes out in CANCER DISCOVERY aacrjournals.org/cancerdiscov... @silkegillessen.bsky.social @aureliusomlin.bsky.social @barbaramelao.bsky.social @achoud72.bsky.social @yukselurun.bsky.social

Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials out on @EurUrolOncol sciencedirect.com/science/arti...

A warm welcome to @ema.europa.eu to Blue Sky!!

Men’s Attitudes Towards Participation in Organised Prostate Cancer Testing www.eu-openscience.europeanurology.com/article/S266... Study underscores importance of clear communication & addressing logistical and psychological barriers to enhance informed decision-making for prostate cancer screening

Incidence and prognostic implications of PSA persistence and relapse after radical prostatectomy. Population-based study academic.oup.com/jnci/advance... The study highlights the importance of these factors in guiding treatment decisions for men with PSA persistence or relapse #ProstateCancer

High-Intensity Focused Ultrasound (HIFU), a non-invasive FDA-approved treatment for localized #ProstateCancer , has shown promise in enhancing antitumor immunity by increasing lymphocyte infiltration into tumors. www.sciencedirect.com/science/arti...

Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant #ProstateCancer sciencedirect.com/science/arti... Study highlights the need for gene-specific selection of patients for optimal treatment outcomes.

AGD1/USP10/METTL13 complexes enhance cancer stem cells proliferation and diminish the therapeutic effect of docetaxel via CD44 m6A modification in castration resistant #ProstateCancer jeccr.biomedcentral.com/articles/10....

Cancer Statistics Just Out for 2025 out on American Cancer Society Journals acsjournals.onlinelibrary.wiley.com/doi/epdf/10.... #ProstateCancer has one of the highest contemporary survival rates at 97%, followed closely by testicular cancer (95%) and melanoma (94%)

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials out on the RedJournal www.redjournal.org/article/S036... Overall, SABR provides durable disease control for localized prostate cancer with manageable risks.

Immunome profiling in #ProstateCancer : a guide for clinicians out in @FrontiersIn Immunology www.frontiersin.org/journals/imm... Review highlights the need for more comprehensive insights into the plasticity and interactions of tumor-infiltrating immune cells to better understand PC biology.

Proud Collaborators of the #OncoAlertColloquium REGISTER for FREE HERE👉 buff.ly/3CChgre February 3-9, 2025 💯% Virtual & Interactive

PARP inhibitors + hormonal therapy boost OS & PFS in BRCA1/2-mutant & HRR-deficient mCRPC. 🧬Olaparib, Talazoparib, & Rucaparib lead efficacy despite AEs. @oncoalert.bsky.social @christianrolfo.bsky.social @apccc.bsky.social @asharpmedonc.bsky.social @weoncologists.bsky.social

Perspectives of clinicians & screening candidates on shared decision-making in #ProstateCancer screening with PSA ebm.bmj.com/content/earl... Study concluded that both patients & professionals support evidence-based tools to enhance SDM and improve collaboration across care levels for PSA testing

Study identifies genes linked to high #ProstateCancer mortality rates www.nature.com/articles/d44... Findings highlight the need for more research involving African populations & could improve cancer risk prediction models, potentially benefiting African American men & others of African ancestry

MRI-directed Micro-US–guided Transperineal Focal Laser Ablation for Localized Prostate Cancer: A 1-year Follow-up Study pubs.rsna.org/doi/10.1148/... At 12 months, the overall recurrence rate was 49%, erectile function decreased, while urinary function remained stable.